Source:http://linkedlifedata.com/resource/pubmed/id/15989459
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-7-1
|
pubmed:abstractText |
The redistribution of mutations related to protease inhibitor (PI) resistance after a PI-sparing regimen in human immunodeficiency virus (HIV)-infected, highly PI-experienced patients was prospectively assessed. Twenty-five patients failing a PI-including regimen were given PI-sparing antiretroviral therapy, and then followed for 24 weeks after PI resumption. Genotyping was performed by direct sequencing before and during the PI-sparing regimen. The median (interquartile range, IQR) baseline CD4+ T-lymphocyte count was 198 (120-255) cells/microl, and the median HIV-RNA level was 82,000 (41,000-300,000) copies/ml. Patients had experienced a median of 4.5 (4-5.25) PIs. The median number of PI mutations was eight (6-9). The PI-sparing regimen consisted of a median of three (3-4) drugs and lasted for a median of 53 (24-67) weeks. At the end of the study, the median number of PI mutations was 6.5 (6-9). The median change in the number of PI mutations was -1 (IQR from -1 to 0). A reduction from baseline was observed in 13 cases (52%); nine (36%) showed no change and three (12%) showed an increased number of PI substitutions. In highly PI-experienced patients, a PI-sparing regimen may lead to a reduction, no change, or increase in the number of PI mutations. The reduction is negligible in most cases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0889-2229
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
545-54
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:15989459-Anti-HIV Agents,
pubmed-meshheading:15989459-CD4 Lymphocyte Count,
pubmed-meshheading:15989459-Drug Administration Schedule,
pubmed-meshheading:15989459-Drug Resistance, Viral,
pubmed-meshheading:15989459-Drug Therapy, Combination,
pubmed-meshheading:15989459-Genetic Variation,
pubmed-meshheading:15989459-Genotype,
pubmed-meshheading:15989459-HIV Infections,
pubmed-meshheading:15989459-HIV Protease,
pubmed-meshheading:15989459-HIV Protease Inhibitors,
pubmed-meshheading:15989459-HIV-1,
pubmed-meshheading:15989459-Humans,
pubmed-meshheading:15989459-Mutation,
pubmed-meshheading:15989459-RNA, Viral,
pubmed-meshheading:15989459-Reverse Transcriptase Inhibitors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.
|
pubmed:affiliation |
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy. nicola.gianotti@hsr.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|